MRM Health Receives CTA Approval for Phase 1b/2a Trial with Next Generation Optimized Consortium Therapeutic MH002 in Ulcerative Colitis


Dear shareholder,

Dear Madam, Dear Sir,


Please find attached the latest press release of MRM Health.


Best regards

Ackermans & van Haaren

Attachment



Pièces jointes

MRM Health press release
GlobeNewswire

Lecture recommandée